VYNE Therapeutics Inc. (VYNE) Social Stream
VYNE THERAPEUTICS INC (VYNE) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering VYNE THERAPEUTICS INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-08-16 | 6 | $14 | $3 | $6.666 | $3.47 | 92.1% |
| 2021-11-11 | 6 | $14 | $3 | $6.5 | $3.47 | 87.32% |
| 2021-12-06 | 4 | $14 | $3 | $7.166 | $3.47 | 106.51% |
| 2022-03-21 | 6 | $14 | $3 | $7.166 | $3.47 | 106.51% |
| 2022-04-07 | 5 | $14 | $3 | $7.166 | $3.47 | 106.51% |
| 2022-05-18 | 5 | $10 | $3 | $5.8 | $3.47 | 67.15% |
| 2022-08-10 | 5 | $10 | $1.5 | $4.7 | $3.47 | 35.45% |
| 2022-08-15 | 5 | $5 | $1.5 | $3.625 | $3.47 | 4.47% |
| 2022-10-11 | 6 | $5 | $1.5 | $3.7 | $3.47 | 6.63% |
| 2022-11-11 | 5 | $89.928 | $26.978 | $69.694 | $3.47 | 1908.47% |
| 2023-03-10 | 5 | $89.93 | $26.978 | $69.694 | $3.47 | 1908.47% |
| 2023-03-14 | 5 | $89.93 | $28 | $69.95 | $3.47 | 1915.85% |
| 2023-05-12 | 3 | $71.941 | $9 | $36.313 | $3.47 | 946.48% |
| 2023-08-15 | 4 | $71.941 | $9 | $36.313 | $3.47 | 946.48% |
| 2023-09-26 | 4 | $28 | $5 | $14 | $3.47 | 303.46% |
| 2023-10-31 | 3 | $5.75 | $5 | $5.375 | $3.47 | 54.9% |
| 2023-11-13 | 3 | $6 | $5 | $5.583 | $3.47 | 60.89% |
The Trend in the Analyst Price Target
VYNE's average price target has moved down $5.85 over the prior 30 months.
VYNE reports an average of 1,088.73% for its upside potential over the past 35 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-03-14 | 4 | 89.93 | 28 | 58.965 | 2.41 | 2346.68% |
| 2023-03-14 | 5 | 89.93 | 28 | 69.950 | 2.41 | 2802.49% |
| 2023-03-14 | 5 | 89.93 | 28 | 58.965 | 2.41 | 2346.68% |
| 2023-10-31 | 3 | 5.75 | 5 | 5.375 | 3.05 | 76.23% |
| 2023-11-05 | 3 | 6.00 | 5 | 5.583 | 3.03 | 84.26% |
VYNE Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 3 | 0 | 0 | 0 | 0 | 3 |
The Trend in the Broker Recommendations
Over the past 27 months, VYNE's average broker recommendation rating improved by 0.67.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In terms of how VYNE THERAPEUTICS INC fares relative to all US stocks, note that its variance in analysts' estimates is lower than -1957.22% of that group.
- VYNE has a higher average analyst price target than 992.93% of stocks in the small market cap category.
- VYNE has a higher number of analysts covering the stock than 553.52% of Healthcare stocks.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, VYNE THERAPEUTICS INC's upside potential (average analyst target price relative to current price) is higher than 1244.96% of them.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to VYNE THERAPEUTICS INC are CUE, ENSC, and NRXP.
View All Top Stocks by Price Target
What is the outlook for VYNE? Use POWR Ratings for clearer insight into price direction.